<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23769961</identifier>
<setSpec>1578-1879</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Guijarro, Carlos</dc:author>
<dc:author>García-Díaz, Juan de Dios</dc:author>
<dc:description xml:lang="en">The European Guidelines on Dyslipidaemias (2011) and Cardiovascular Prevention (2012) have incorporated important changes. Firstly, it highlights the identification of a group of "very high risk" patients: patients with atherosclerotic disease in any vascular area, diabetes with associated risk factors, advanced chronic renal failure, or a SCORE estimate &gt;10%. Patients with diabetes and no other risk factors, moderate renal failure, severe hypertension, genetic dyslipidaemias, or a SCORE estimate 5-10%, are considered as "high risk". The HDL cholesterol and triglycerides levels are considered as modulators of risks, but not therapeutic objectives per se. The therapeutic objectives are set at LDL cholesterol levels &lt; 70 mg/dl (or at least a reduction of at least 50%) for patients at very high risk, and an LDL &lt; 100 mg/dl for high risk patients. As well as the changes in lifestyle, pharmacological treatment with statins is the focal point of lipid lowering treatments. Other pharmacological options may be considered if the treatment with the maximum tolerable doses of statins do not achieve the therapeutic objectives.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Treatment goals</dc:subject>
<dc:subject>LDL - cholesterol</dc:subject>
<dc:subject>Objetivos terapéuticos</dc:subject>
<dc:subject>Colesterol LDL</dc:subject>
<dc:subject>Prevención cardiovascular</dc:subject>
<dc:subject>Estatinas</dc:subject>
<dc:subject>Dyslipidemia</dc:subject>
<dc:subject>Cardiovascular prevention</dc:subject>
<dc:subject>Dislipidemia</dc:subject>
<dc:subject>Guías terapéuticas</dc:subject>
<dc:subject>Statins</dc:subject>
<dc:subject>Guidelines</dc:subject>
<dc:date>2013 Apr-Jun </dc:date>
<dc:title xml:lang="es">Estrategias terapéuticas. Evolución y estado actual de las Guías Europeas de Prevención Cardiovascular.</dc:title>
<dc:title xml:lang="en">[Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention].</dc:title>
<dc:publisher>Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis</dc:publisher>
</metadata>
</record>
</pubmed-document>
